CONTEXT: Molecular diagnostics allow for rapid identification and detection of resistance markers of bloodstream infection, with a potential for accelerated antimicrobial optimization and improved patient outcomes. Although the impact of rapid diagnosis has been reported, studies in pediatric patients are scarce. OBJECTIVE: To determine the impact of a molecular blood-culture assay that identifies a broad-spectrum of pathogens and resistance markers in pediatric patients with gram-positive bloodstream infections. DESIGN: Data on the time to antimicrobial optimization, the length of hospitalization, and the hospital cost following implementation of a rapid assay were prospectively collected and compared with corresponding preimplementation data. RESULTS: There were 440 episodes from 383 patients included, 221 preimplementation episodes and 219 postimplementation episodes. Overall time to antimicrobial optimization was shortened by 12.5 hours (P = .006), 11.9 hours (P = .005) for bloodstream infections of Staphylococcus aureus specifically. Duration of antibiotics for those with probable blood-culture contamination with coagulase-negative staphylococci was reduced by 36.9 hours (P < .001). Median length of stay for patients admitted to general pediatric units was 1.5 days shorter (P = .04), and median hospital cost was $3757 (P = .03) less after implementation. For S aureus bloodstream infections, median length of stay and hospital cost were decreased by 5.6 days (P = .01) and $13,341 (P = .03), respectively. CONCLUSIONS: Implementation of molecular assay for the detection of gram-positive pathogens and resistance markers significantly reduced time to identification and resistance detection, resulting in accelerated optimization of therapy, shorter length of stay, and decreased health care cost.
CONTEXT: Molecular diagnostics allow for rapid identification and detection of resistance markers of bloodstream infection, with a potential for accelerated antimicrobial optimization and improved patient outcomes. Although the impact of rapid diagnosis has been reported, studies in pediatric patients are scarce. OBJECTIVE: To determine the impact of a molecular blood-culture assay that identifies a broad-spectrum of pathogens and resistance markers in pediatric patients with gram-positive bloodstream infections. DESIGN: Data on the time to antimicrobial optimization, the length of hospitalization, and the hospital cost following implementation of a rapid assay were prospectively collected and compared with corresponding preimplementation data. RESULTS: There were 440 episodes from 383 patients included, 221 preimplementation episodes and 219 postimplementation episodes. Overall time to antimicrobial optimization was shortened by 12.5 hours (P = .006), 11.9 hours (P = .005) for bloodstream infections of Staphylococcus aureus specifically. Duration of antibiotics for those with probable blood-culture contamination with coagulase-negative staphylococci was reduced by 36.9 hours (P < .001). Median length of stay for patients admitted to general pediatric units was 1.5 days shorter (P = .04), and median hospital cost was $3757 (P = .03) less after implementation. For S aureus bloodstream infections, median length of stay and hospital cost were decreased by 5.6 days (P = .01) and $13,341 (P = .03), respectively. CONCLUSIONS: Implementation of molecular assay for the detection of gram-positive pathogens and resistance markers significantly reduced time to identification and resistance detection, resulting in accelerated optimization of therapy, shorter length of stay, and decreased health care cost.
Authors: Ayesha Khan; William R Miller; Dierdre Axell-House; Jose M Munita; Cesar A Arias Journal: J Clin Microbiol Date: 2022-06-13 Impact factor: 11.677
Authors: Alex van Belkum; Carey-Ann D Burnham; John W A Rossen; Frederic Mallard; Olivier Rochas; William Michael Dunne Journal: Nat Rev Microbiol Date: 2020-02-13 Impact factor: 60.633
Authors: Angela Fimbres Veesenmeyer; Jared A Olson; Adam L Hersh; Chris Stockmann; Kent Korgenski; Emily A Thorell; Andrew T Pavia; Anne J Blaschke Journal: Infect Dis Ther Date: 2016-11-10
Authors: Luke W Anson; Kevin Chau; Nicholas Sanderson; Sarah Hoosdally; Phelim Bradley; Zamin Iqbal; Hang Phan; Dona Foster; Sarah Oakley; Marcus Morgan; Tim E A Peto; Derrick W Crook; Louise J Pankhurst Journal: J Med Microbiol Date: 2018-01-10 Impact factor: 2.472
Authors: Paul A Granato; Melissa M Unz; Raymond H Widen; Suzane Silbert; Stephen Young; Kathryn L Heflin; Matt S Conover; Blake W Buchan; Nathan A Ledeboer Journal: J Clin Microbiol Date: 2018-08-27 Impact factor: 5.948
Authors: Andrew Ticcioni; Kyle Piscitello; Matthew Bjornstad; Katie Hensley; Jim Davis; Annette Drobac; John Canepa Journal: Innov Pharm Date: 2021-04-15